Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
Identifieur interne : 001048 ( Main/Exploration ); précédent : 001047; suivant : 001049Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
Auteurs : Davide Corti [Suisse] ; Nadia Passini [Suisse] ; Antonio Lanzavecchia [Suisse] ; Maria Zambon [Royaume-Uni]Source :
- Journal of Infection and Public Health [ 1876-0341 ] ; 2016.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (isolement et purification), Anticorps antiviraux (pharmacologie), Anticorps monoclonaux (isolement et purification), Anticorps monoclonaux (pharmacologie), Biotechnologie (), Cellules CHO, Cricetulus, Facteurs immunologiques (isolement et purification), Facteurs immunologiques (pharmacologie), Facteurs temps, Humains, Immunothérapie (), Infections à coronavirus (), Technologie pharmaceutique ().
- MESH :
- isolement et purification : Anticorps antiviraux, Anticorps monoclonaux, Facteurs immunologiques.
- pharmacologie : Anticorps antiviraux, Anticorps monoclonaux, Facteurs immunologiques.
- Animaux, Biotechnologie, Cellules CHO, Cricetulus, Facteurs temps, Humains, Immunothérapie, Infections à coronavirus, Technologie pharmaceutique.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (isolation & purification), Antibodies, Monoclonal (pharmacology), Antibodies, Viral (isolation & purification), Antibodies, Viral (pharmacology), Biotechnology (methods), CHO Cells, Coronavirus Infections (prevention & control), Coronavirus Infections (therapy), Cricetulus, Humans, Immunologic Factors (isolation & purification), Immunologic Factors (pharmacology), Immunotherapy (methods), Technology, Pharmaceutical (methods), Time Factors.
- MESH :
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Viral, Immunologic Factors.
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Viral, Immunologic Factors.
- methods : Biotechnology, Immunotherapy, Technology, Pharmaceutical.
- prevention & control : Coronavirus Infections.
- therapy : Coronavirus Infections.
- Animals, CHO Cells, Cricetulus, Humans, Time Factors.
Abstract
The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.
Url:
DOI: 10.1016/j.jiph.2016.04.003
PubMed: 27102927
PubMed Central: 7102728
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000E53
- to stream Pmc, to step Curation: 000E53
- to stream Pmc, to step Checkpoint: 000A24
- to stream PubMed, to step Corpus: 001155
- to stream PubMed, to step Curation: 001155
- to stream PubMed, to step Checkpoint: 002A32
- to stream Ncbi, to step Merge: 001586
- to stream Ncbi, to step Curation: 001586
- to stream Ncbi, to step Checkpoint: 001586
- to stream Main, to step Merge: 001052
- to stream Main, to step Curation: 001048
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome</title><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:aff id="aff0005">Humabs BioMed SA, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name><affiliation wicri:level="1"><nlm:aff id="aff0005">Humabs BioMed SA, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff0015">Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich</wicri:regionArea><wicri:noRegion>8093 Zurich</wicri:noRegion></affiliation></author><author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name><affiliation wicri:level="1"><nlm:aff id="aff0020">Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Microbiology Services Colindale, Public Health England, London NW9 5HT</wicri:regionArea><wicri:noRegion>London NW9 5HT</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27102927</idno><idno type="pmc">7102728</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102728</idno><idno type="RBID">PMC:7102728</idno><idno type="doi">10.1016/j.jiph.2016.04.003</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000E53</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000E53</idno><idno type="wicri:Area/Pmc/Curation">000E53</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000E53</idno><idno type="wicri:Area/Pmc/Checkpoint">000A24</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A24</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:27102927</idno><idno type="wicri:Area/PubMed/Corpus">001155</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001155</idno><idno type="wicri:Area/PubMed/Curation">001155</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001155</idno><idno type="wicri:Area/PubMed/Checkpoint">002A32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A32</idno><idno type="wicri:Area/Ncbi/Merge">001586</idno><idno type="wicri:Area/Ncbi/Curation">001586</idno><idno type="wicri:Area/Ncbi/Checkpoint">001586</idno><idno type="wicri:doubleKey">1876-0341:2016:Corti D:rapid:generation:of</idno><idno type="wicri:Area/Main/Merge">001052</idno><idno type="wicri:Area/Main/Curation">001048</idno><idno type="wicri:Area/Main/Exploration">001048</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome</title><author><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name><affiliation wicri:level="1"><nlm:aff id="aff0005">Humabs BioMed SA, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name><affiliation wicri:level="1"><nlm:aff id="aff0005">Humabs BioMed SA, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Humabs BioMed SA, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation></author><author><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><affiliation wicri:level="1"><nlm:aff id="aff0010">Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Immune Regulation Unit, Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona</wicri:regionArea><wicri:noRegion>6500 Bellinzona</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:aff id="aff0015">Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Microbiology, Eidgenössische Technische Hochschule Zurich, 8093 Zurich</wicri:regionArea><wicri:noRegion>8093 Zurich</wicri:noRegion></affiliation></author><author><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name><affiliation wicri:level="1"><nlm:aff id="aff0020">Microbiology Services Colindale, Public Health England, London NW9 5HT, United Kingdom</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Microbiology Services Colindale, Public Health England, London NW9 5HT</wicri:regionArea><wicri:noRegion>London NW9 5HT</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of Infection and Public Health</title><idno type="ISSN">1876-0341</idno><idno type="eISSN">1876-035X</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (isolation & purification)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Viral (isolation & purification)</term><term>Antibodies, Viral (pharmacology)</term><term>Biotechnology (methods)</term><term>CHO Cells</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (therapy)</term><term>Cricetulus</term><term>Humans</term><term>Immunologic Factors (isolation & purification)</term><term>Immunologic Factors (pharmacology)</term><term>Immunotherapy (methods)</term><term>Technology, Pharmaceutical (methods)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (isolement et purification)</term><term>Anticorps antiviraux (pharmacologie)</term><term>Anticorps monoclonaux (isolement et purification)</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Biotechnologie ()</term><term>Cellules CHO</term><term>Cricetulus</term><term>Facteurs immunologiques (isolement et purification)</term><term>Facteurs immunologiques (pharmacologie)</term><term>Facteurs temps</term><term>Humains</term><term>Immunothérapie ()</term><term>Infections à coronavirus ()</term><term>Technologie pharmaceutique ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biotechnology</term><term>Immunotherapy</term><term>Technology, Pharmaceutical</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CHO Cells</term><term>Cricetulus</term><term>Humans</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Biotechnologie</term><term>Cellules CHO</term><term>Cricetulus</term><term>Facteurs temps</term><term>Humains</term><term>Immunothérapie</term><term>Infections à coronavirus</term><term>Technologie pharmaceutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p>The last century has witnessed the emergence of several previously unknown viruses as life-threatening human pathogens. Several examples include HIV, Ebola, Lujo, and, most recently, the Middle East respiratory syndrome (MERS) and Ebola. In this study, we describe a method for the swift generation of a human-derived monoclonal antibody, known as LCA60, as a treatment for MERS infections. LCA60 antibody was generated using the Cellclone Technology from the immortalized B cells of a human donor recovering from MERS. Only four months were required from the initial screening of B cells to the development of a stable CHO cell line suitable for the production of clinical grade antibody, thereby delineating a rapid pathway for the development of antiviral therapies against emerging viruses. Currently, the LCA60 antibody is being considered for clinical development, which includes prophylaxis in individuals at risk and a treatment for severe MERS-CoV infections.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Arabi, Y M" uniqKey="Arabi Y">Y.M. Arabi</name></author><author><name sortKey="Arifi, A A" uniqKey="Arifi A">A.A. Arifi</name></author><author><name sortKey="Balkhy, H H" uniqKey="Balkhy H">H.H. Balkhy</name></author><author><name sortKey="Najm, H" uniqKey="Najm H">H. Najm</name></author><author><name sortKey="Aldawood, A S" uniqKey="Aldawood A">A.S. Aldawood</name></author><author><name sortKey="Ghabashi, A" uniqKey="Ghabashi A">A. Ghabashi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author><author><name sortKey="Dhahiry Al, S H S" uniqKey="Dhahiry Al S">S.H.S. Dhahiry Al</name></author><author><name sortKey="Reusken, C B E M" uniqKey="Reusken C">C.B.E.M. Reusken</name></author><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author><author><name sortKey="Galiano, M" uniqKey="Galiano M">M. Galiano</name></author><author><name sortKey="Myers, R" uniqKey="Myers R">R. Myers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Osterhaus, A D M E" uniqKey="Osterhaus A">A.D.M.E. Osterhaus</name></author><author><name sortKey="Fouchier, R A M" uniqKey="Fouchier R">R.A.M. Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bermingham, A" uniqKey="Bermingham A">A. Bermingham</name></author><author><name sortKey="Chand, M A" uniqKey="Chand M">M.A. Chand</name></author><author><name sortKey="Brown, C S" uniqKey="Brown C">C.S. Brown</name></author><author><name sortKey="Aarons, E" uniqKey="Aarons E">E. Aarons</name></author><author><name sortKey="Tong, C" uniqKey="Tong C">C. Tong</name></author><author><name sortKey="Langrish, C" uniqKey="Langrish C">C. Langrish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A. McGeer</name></author><author><name sortKey="Perl, T M" uniqKey="Perl T">T.M. Perl</name></author><author><name sortKey="Price, C S" uniqKey="Price C">C.S. Price</name></author><author><name sortKey="Al Rabeeah, A A" uniqKey="Al Rabeeah A">A.A. Al Rabeeah</name></author><author><name sortKey="Cummings, D A T" uniqKey="Cummings D">D.A.T. Cummings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mair Jenkins, J" uniqKey="Mair Jenkins J">J. Mair-Jenkins</name></author><author><name sortKey="Saavedra Campos, M" uniqKey="Saavedra Campos M">M. Saavedra-Campos</name></author><author><name sortKey="Baillie, J K" uniqKey="Baillie J">J.K. Baillie</name></author><author><name sortKey="Cleary, P" uniqKey="Cleary P">P. Cleary</name></author><author><name sortKey="Khaw, F M" uniqKey="Khaw F">F.-M. Khaw</name></author><author><name sortKey="Lim, W S" uniqKey="Lim W">W.S. Lim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Traggiai, E" uniqKey="Traggiai E">E. Traggiai</name></author><author><name sortKey="Becker, S" uniqKey="Becker S">S. Becker</name></author><author><name sortKey="Subbarao, K" uniqKey="Subbarao K">K. Subbarao</name></author><author><name sortKey="Kolesnikova, L" uniqKey="Kolesnikova L">L. Kolesnikova</name></author><author><name sortKey="Uematsu, Y" uniqKey="Uematsu Y">Y. Uematsu</name></author><author><name sortKey="Gismondo, M R" uniqKey="Gismondo M">M.R. Gismondo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corti, D" uniqKey="Corti D">D. Corti</name></author><author><name sortKey="Lanzavecchia, A" uniqKey="Lanzavecchia A">A. Lanzavecchia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corti, D" uniqKey="Corti D">D. Corti</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Pedotti, M" uniqKey="Pedotti M">M. Pedotti</name></author><author><name sortKey="Simonelli, L" uniqKey="Simonelli L">L. Simonelli</name></author><author><name sortKey="Agnihothram, S" uniqKey="Agnihothram S">S. Agnihothram</name></author><author><name sortKey="Fett, C" uniqKey="Fett C">C. Fett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burton, D R" uniqKey="Burton D">D.R. Burton</name></author><author><name sortKey="Saphire, E O" uniqKey="Saphire E">E.O. Saphire</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borio, L" uniqKey="Borio L">L. Borio</name></author><author><name sortKey="Cox, E" uniqKey="Cox E">E. Cox</name></author><author><name sortKey="Lurie, N" uniqKey="Lurie N">N. Lurie</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Royaume-Uni</li><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Corti, Davide" sort="Corti, Davide" uniqKey="Corti D" first="Davide" last="Corti">Davide Corti</name></noRegion><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Lanzavecchia, Antonio" sort="Lanzavecchia, Antonio" uniqKey="Lanzavecchia A" first="Antonio" last="Lanzavecchia">Antonio Lanzavecchia</name><name sortKey="Passini, Nadia" sort="Passini, Nadia" uniqKey="Passini N" first="Nadia" last="Passini">Nadia Passini</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Zambon, Maria" sort="Zambon, Maria" uniqKey="Zambon M" first="Maria" last="Zambon">Maria Zambon</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001048 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001048 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:7102728
|texte= Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27102927" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |